CYP2A6 Genotypes and Coumarin-oxidation Phenotypes in a Thai Population and Their Relationship to Tobacco Smoking

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2008 Dec 17

PMID 19082995

Citations 3

Authors

Wiratchanee Mahavorasirikul

Wichittra Tassaneeyakul

Soisagwan Satarug

Ronnatrai Reungweerayut

Chacrin Na-Bangchang

Kesara Na-Bangchang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the association between polymorphisms in the human CYP2A6 gene, CYP2A6 enzyme activity and the influence of cigarette smoking in a Thai population.

Methods: Coumarin (5 mg capsule) was administered to 194 healthy Thai subjects. Genetic variation of the CYP2A6 gene was identified using PCR methods. The excreted dose of 7-hydroxycoumarin (as a percentage of the urine concentration) 2 h after administration was calculated as an index of coumarin metabolism.

Results: The frequencies of CYP2A6 alleles *1A, *1B, *4C, *7, *8, *9 and *10 were 34.0, 35.3, 9.3, 6.4, 0.5, 12.1 and 2.4%, respectively. Of the 194 subjects tested, the number (percentages) of Thai participants classified as ultra-rapid, extensive, intermediate and poor metabolizers were 8 (4.1%), 159 (82.0%) 22 (11.3%) and five (2.6%), respectively.

Conclusion: A relationship between the interindividual differences in coumarin metabolism and genetic polymorphisms of the CYP2A6 gene was observed.

Citing Articles

Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Lopez-Flores L, Perez-Rubio G, Falfan-Valencia R EXCLI J. 2017; 16:174-196.

PMID: 28507465 PMC: 5427481. DOI: 10.17179/excli2016-847.

Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.

Phompradit P, Muhamad P, Cheoymang A, Na-Bangchang K Am J Trop Med Hyg. 2014; 91(2):361-6.

PMID: 24891466 PMC: 4125263. DOI: 10.4269/ajtmh.13-0531.

High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Aklillu E, Djordjevic N, Carrillo J, Makonnen E, Bertilsson L, Ingelman-Sundberg M OMICS. 2014; 18(7):446-53.

PMID: 24380444 PMC: 4086241. DOI: 10.1089/omi.2013.0140.

References

Xu C, Rao Y, Xu B, Hoffmann E, Jones J, Sellers E . An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun. 2002; 290(1):318-24. DOI: 10.1006/bbrc.2001.6209. View

Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T . Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther. 2000; 67(1):57-69. DOI: 10.1067/mcp.2000.103957. View

Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon J, Yokoi T . Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther. 2003; 74(1):69-76. DOI: 10.1016/S0009-9236(03)00090-0. View

Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S . Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics. 2003; 13(11):689-95. DOI: 10.1097/00008571-200311000-00005. View

Kwon J, Nakajima M, Chai S, Yom Y, Kim H, Yamazaki H . Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 2001; 11(4):317-23. DOI: 10.1097/00008571-200106000-00006. View

Nakajima M, Kwon J, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H . Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther. 2001; 69(1):72-8. DOI: 10.1067/mcp.2001.112688. View

Oscarson M, McLellan R, Gullsten H, Yue Q, Lang M, Bernal M . Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999; 448(1):105-10. DOI: 10.1016/s0014-5793(99)00359-2. View

Pianezza M, Sellers E, Tyndale R . Nicotine metabolism defect reduces smoking. Nature. 1998; 393(6687):750. DOI: 10.1038/31623. View

Ujjin P, Satarug S, Vanavanitkun Y, Daigo S, Ariyoshi N, Yamazaki H . Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics. 2002; 12(3):241-9. DOI: 10.1097/00008571-200204000-00009. View

10.

Egan D, OKennedy R, Moran E, Cox D, Prosser E, Thornes R . The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev. 1990; 22(5):503-29. DOI: 10.3109/03602539008991449. View

11.

Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M . Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun. 2001; 284(2):455-60. DOI: 10.1006/bbrc.2001.4990. View

12.

Yoshida R, Nakajima M, Watanabe Y, Kwon J, Yokoi T . Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol. 2002; 54(5):511-7. PMC: 1874463. DOI: 10.1046/j.1365-2125.2002.01667.x. View

13.

Kitagawa K, Kunugita N, Katoh T, Yang M, Kawamoto T . The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem Biophys Res Commun. 1999; 262(1):146-51. DOI: 10.1006/bbrc.1999.1182. View

14.

Satarug S, Tassaneeyakul W, Na-Bangchang K, Cashman J, Moore M . Genetic and environmental influences on therapeutic and toxicity outcomes: studies with CYP2A6. Curr Clin Pharmacol. 2008; 1(3):291-309. DOI: 10.2174/157488406778249343. View

15.

Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T . In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet. 2007; 21(6):475-84. DOI: 10.2133/dmpk.21.475. View

16.

Rautio A, KRAUL H, Kojo A, Salmela E, Pelkonen O . Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics. 1992; 2(5):227-33. DOI: 10.1097/00008571-199210000-00005. View

17.

He X, Shen J, Hu W, Ding X, Lu A, Hong J . Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys. 2004; 427(2):143-53. DOI: 10.1016/j.abb.2004.03.016. View

18.

Hoult J, Paya M . Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol. 1996; 27(4):713-22. DOI: 10.1016/0306-3623(95)02112-4. View

19.

Ariyoshi N, Sawamura Y, Kamataki T . A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001; 281(3):810-4. DOI: 10.1006/bbrc.2001.4422. View

20.

Poland R, Pechnick R, Cloak C, Wan Y, Nuccio I, Lin K . Effect of cigarette smoking on coumarin metabolism in humans. Nicotine Tob Res. 2001; 2(4):351-4. DOI: 10.1080/713688151. View